Edition:
India

Roche Says Actemra/Roactemra Reduce Mechanical Ventilation Risk In COVID-19 Patients


Friday, 18 Sep 2020 

Sept 18 (Reuters) - Roche Holding AG ::ROCHE’S PHASE III EMPACTA STUDY SHOWED ACTEMRA/ROACTEMRA REDUCED THE LIKELIHOOD OF NEEDING MECHANICAL VENTILATION IN HOSPITALISED PATIENTS WITH COVID-19 ASSOCIATED PNEUMONIA.EMPACTA IS FIRST GLOBAL PHASE III TRIAL TO SHOW EFFICACY WITH ACTEMRA/ROACTEMRA IN COVID-19 ASSOCIATED PNEUMONIA AND FIRST WITH A FOCUS ON ENROLLING LARGELY UNDERSERVED AND MINORITY PATIENTS.NO STATISTICAL DIFFERENCE IN MORTALITY BETWEEN PATIENTS WHO RECEIVED ACTEMRA/ROACTEMRA OR PLACEBO.ROCHE PLANS TO SHARE THESE RESULTS WITH HEALTH AUTHORITIES, INCLUDING US FDA.EMPACTA STUDY DID NOT IDENTIFY ANY NEW SAFETY SIGNALS FOR ACTEMRA/ROACTEMRA. 

Company Quote

41.225
-0.455 -1.09%
23 Nov 2020